Skip to main content
. 2021 Mar 2;8(3):e975. doi: 10.1212/NXI.0000000000000975

Figure 3. Anti-CD20 Depletes Peripheral B Cells in the DTH-TLS Model.

Figure 3

DTH-TLS lesions were established in huCD20 mice. Forty days after lesion induction, the mice were treated with either type I anti-CD20, type II anti-CD20, or a vehicle control. Twenty days after treatment, blood and organs were collected and analyzed. (A and C) Both type II and type I therapy caused a reduction in B cells in the spleen. Type II depleted splenic B cells better than type I. (B) The B-cell proportion in the lymph nodes was also reduced after both type I and II treatment. There was no difference between the 2 treatment antibodies. (D) The number of circulating white blood cells was reduced after anti-CD20 therapy. (E) Type I and II both reduced the number of blood lymphocytes compared with controls. Data are mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Statistics: 1-way ANOVA with Tukey multiple comparisons test (type I n = 9, type II n = 11, control n = 13). ANOVA = analysis of variance; TLS = tertiary lymphoid structures; WBC, white blood cell.